tiprankstipranks
Trending News
More News >
CASI Pharmaceuticals (CASI)
NASDAQ:CASI
Advertisement

CASI Pharmaceuticals (CASI) Price & Analysis

Compare
460 Followers

CASI Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Debt ReductionThe sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.
Product DevelopmentCID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.
Bears Say
Financial LossCASI reported a net loss of $0.69 per share for the quarter, which is higher than the consensus estimated net loss of $0.61 per share.
Revenue DeclineThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.

CASI Pharmaceuticals News

CASI FAQ

What was CASI Pharmaceuticals’s price range in the past 12 months?
CASI Pharmaceuticals lowest stock price was $1.09 and its highest was $7.67 in the past 12 months.
    What is CASI Pharmaceuticals’s market cap?
    CASI Pharmaceuticals’s market cap is $35.48M.
      When is CASI Pharmaceuticals’s upcoming earnings report date?
      CASI Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 74 days.
        How were CASI Pharmaceuticals’s earnings last quarter?
        Currently, no data Available
        Is CASI Pharmaceuticals overvalued?
        According to Wall Street analysts CASI Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does CASI Pharmaceuticals pay dividends?
          CASI Pharmaceuticals does not currently pay dividends.
          What is CASI Pharmaceuticals’s EPS estimate?
          CASI Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does CASI Pharmaceuticals have?
          CASI Pharmaceuticals has 15,492,681 shares outstanding.
            What happened to CASI Pharmaceuticals’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of CASI Pharmaceuticals?
            Currently, no hedge funds are holding shares in CASI

            Company Description

            CASI Pharmaceuticals

            CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

            CASI Pharmaceuticals (CASI) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Curis
            GeoVax Labs
            Moleculin Biotech
            Pulmatrix
            Elevation Oncology

            Ownership Overview

            9.20%0.12%13.66%77.02%
            9.20%
            Insiders
            13.66% Other Institutional Investors
            77.02% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis